Page 323 - Vitamin D and Cancer

310 M. Fakih et al.

7. Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune
diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80(6 Suppl):1678S–1688S
8. Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D suffi-
ciency: implications for establishing a new effective dietary intake recommendation for
vitamin D. J Nutr 135(2):317–322
9. Heaney RP (2004) Functional indices of vitamin D status and ramifications of vitamin D
deficiency. Am J Clin Nutr 80(6 Suppl):1706S–1709S
10. Prosser DE, Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D.
Trends Biochem Sci 29(12):664–673
11. Okuda K, Usui E, Ohyama Y (1995) Recent progress in enzymology and molecular biology
of enzymes involved in vitamin D metabolism. J Lipid Res 36(8):1641–1652
12. Beckman MJ et al (1996) Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic
enzyme. Biochemistry 35(25):8465–8472
13. Omdahl JL, Morris HA, May BK (2002) Hydroxylase enzymes of the vitamin D pathway:
expression, function, and regulation. Annu Rev Nutr 22:139–166
14. Miller GJ et al (1995) Vitamin D receptor expression, 24-hydroxylase activity, and inhibition
of growth by 1alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
Clin Cancer Res 1(9):997–1003
15. Jones G et al (1999) Expression and activity of vitamin D-metabolizing cytochrome P450s
(CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology
140(7):3303–3310
16. Anderson MG et al (2006) Expression of VDR and CYP24A1 mRNA in human tumors.
Cancer Chemother Pharmacol 57(2):234–240
17. Mimori K et al (2004) Clinical significance of the overexpression of the candidate oncogene
CYP24 in esophageal cancer. Ann Oncol 15(2):236–241
18. Gupta RP et al (2004) CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone
Miner Res 19(4):680–688
19. Xu Y et al (2006) Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha, 25-dihy-
droxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 69(1):56–65
20. Zhou C et al (2006) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates
CYP24 expression and drug-induced osteomalacia. J Clin Invest 116(6):1703–1712
21. Holick MF (1990) The use and interpretation of assays for vitamin D and its metabolites.
J Nutr 120(Suppl 11):1464–1469
22. Zerwekh JE (2004) The measurement of vitamin D: analytical aspects. Ann Clin Biochem
41(Pt 4):272–281
23. Wootton AM (2005) Improving the measurement of 25-hydroxyvitamin D. Clin Biochem Rev
26(1):33–36
24. Grant WB, Holick MF (2005) Benefits and requirements of vitamin D for optimal health: a
review. Altern Med Rev 10(2):94–111
25. Lensmeyer GL et al (2006) HPLC method for 25-hydroxyvitamin D measurement: compari-
son with contemporary assays. Clin Chem 52(6):1120–1126
26. Binkley N et al (2008) Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol
Metab 93(5):1804–1808
27. Roth HJ et al (2008) Accuracy and clinical implications of seven 25-hydroxyvitamin D meth-
ods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann
Clin Biochem 45(Pt 2):153–159
28. Insert P (2001) Nichol ADVANTAGE 25-hydroxyvitamin D assay. Nichols Institute
Diagnosis, San Juan Capistrano, CA
29. Product insert (2004) LIAISON chemoluminescence 25-hydroxyvitamin D assay. DiaSorin
Corporation, Still Water, MN
30. Vitamin D External Quality Assessment Scheme (DEQAS) 25(OH)D report (2002). Charing
Cross Hospital London, UK
31. Vitamin D External Quality Assessment Scheme (DEQAS) 25(OH)D report (2004) Charing
Cross Hospital, London UK